Statement by 100 Days Mission partners on the conclusion of the UN High-Level Meeting on Pandemic Prevention, Preparedness and Response

Last week, world leaders  gathered at the United Nations High-Level Meeting on Pandemic Prevention, Preparedness and Response (PPPR). Partners of the 100 Days Mission reaffirm the case for a shared, time-bound goal: ensuring that diagnostics, therapeutics and vaccines are developed and ready for scale up within the first 100 days of a future pandemic threat and that this goal is reflected in the outcomes of this process. Rapidly developing and delivering medical countermeasures is fundamental to protecting lives, reducing economic disruption and strengthening global health security.   

We note with disappointment that the Political Declaration was not adopted at the High-Level Meeting. We are, however, pleased that the100 Days Mission was included in the draft Declaration and that there was widespread support for it throughout the week in New York and at the UN HLM itself.  We urge all Member States to join together in endorsing this critical commitment to pandemic preparedness.  

The case for its inclusion reflects growing international recognition that long-term investments in research and development that integrates equitable access by design central to pandemic preparedness. 

The recent Ebola Bundibugyo virus outbreak has demonstrated that outbreak threats remain unpredictable and that preparedness must extend across pathogen families, including those that are rare or historically neglected. Investments made long before crises occur remain essential to ensuring that promising diagnostics, therapeutics and vaccines can be rapidly developed, evaluated, authorised, manufactured and equitably delivered when new threats emerge. 

100 Days Mission partners also call on Member States to ensure that the outcomes of this process reflect the importance of geographically diversified research, development and manufacturing capacity, equitable access to medical countermeasures, strengthened regulatory systems, resilient health systems, and sustainable financing for preparedness as well as surge financing for rapid response. Together, these elements would provide a strong foundation for a more coordinated and effective global architecture for pandemic prevention, preparedness and response (PPPR).  

Formal recognition of the 100 Days Mission in the Declaration will be a significant milestone, but delivery will always be the true measure of success. Achieving this ambition will require sustained political leadership, predictable financing, rapid sharing of scientific information across borders, ready-to-activate research and manufacturing networks, regulatory preparedness, and strong national and regional preparedness plans that are regularly tested and exercised. In addition, readiness should be defined not only in terms of scientific achievement but also equitable access. 

The focus must now turn to implementation. 100 Days Mission partners encourage Member States to translate their commitments on pandemic preparedness into concrete implementation plans at national, regional, and global levels. This means investing in the capabilities, partnerships and enabling policies needed to rapidly develop, manufacture and deploy safe, effective and affordable diagnostics, therapeutics and vaccines. Equitable access must be embedded throughout this process, from research and development, through to manufacturing, deployment and delivery. Member States should also continue to strengthen areas where gaps remain, including more coherent approaches to PPPR monitoring that identify critical gaps, support countries in addressing them, and help track progress over time.  

Encouragingly, a growing number of countries and regional bodies are already adapting the 100 Days Mission framework within their preparedness strategies, demonstrating how global ambition can be translated into practical capabilities and operational readiness. 

Together with the adoption of the WHO Pandemic Agreement, the International Health Regulations, and ongoing efforts to strengthen the wider PPPR architecture, the the High-Level Meeting provided an opportunity to turn political ambition into measurable preparedness gains and accelerate progress towards the 100 Days Mission.  

100 Days Mission partners stand ready to support Member States in turning these commitments into practical results that improve readiness for future health emergencies.  

Signatory organisations 

• International Pandemic Preparedness Secretariat (IPPS)
• South African Medical Research Council 
• FIND
• Fiocruz
• International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) 
• Coalition for Epidemic Preparedness Innovations (CEPI) 
• Pasteur Network 
• Drugs for Neglected Diseases initiative (DNDi) 
• Medicines Patent Pool (MPP)
• Unitaid 
• Rani (Resilience Action Network International) 
• IAVI 
• Impact Global Health
• INTREPID Alliance